Pharmaceuticals
CATUG and Crystal Bio Establish Strategic Partnership, Launching "CATUG-Crystal" Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
CAMBRIDGE, Mass. and CRANBURY, N.J., Feb. 22, 2024 /PRNewswire/ -- CATUG Inc. (CATUG) andCrystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services. CATUG, a distinguished global entity specializin...
2024-02-22 21:00
1174
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology. This is the first recorded tria...
2024-02-21 22:00
1279
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets
OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. ( Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; "Inveni...
2024-02-21 11:56
1059
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors again...
2024-02-20 22:30
1325
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malignant solid tumor was approved by the U.S. Food and Drug Admi...
2024-02-20 22:00
1165
FDA Grants Orphan Drug Designation to 9MW3011
SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...
2024-02-20 22:00
1175
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...
2024-02-20 21:00
2741
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)
HEFEI, China, Feb. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, autoimmune diseases, and inflammation, through targeted protein degradation technology, today announced th...
2024-02-20 20:00
1038
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.
WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused byND4 mutati...
2024-02-19 19:30
1127
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...
2024-02-18 20:50
1761
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...
2024-02-15 11:37
1293
YS Biopharma Announces Appointment of New Directors
GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...
2024-02-14 20:50
3376
GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024
* Recent updates on its development of LSD treatments were presented YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced onFeb. 14th that it has presented the development updates on its LSD (Lysosomal Storage D...
2024-02-14 16:33
1509
E-Home Household Services Holdings Limited's subsidiary Zhongrun Pharmaceutical intends to acquire NBL (New Zealand) Limited to help expand the international market
FUZHOU, China, Feb. 8, 2024 /PRNewswire/ -- E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider inChina, announced that its subsidiary, Zhongrun (Fujian) Pharmaceutical Co., Ltd, intends to acquire NBL (New Zealand) Limited ("NB...
2024-02-08 22:00
4506
First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)
INCHEON, South Korea, Feb. 7, 2024 /PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for Pulmonary Arterial Hypertension (PAH) has been initiated. The placebo-controlled phase 1 trial designed to a...
2024-02-08 11:53
1327
Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT
Companies will work together to offer fast, cost-effective
ultra-high-throughput library preparation workflows
SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ --
Complete Genomics,
2024-02-07 22:00
1336
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech * Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reduc...
2024-02-07 19:00
1259
Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia
CHENGDU, China, Feb. 5, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA). This ...
2024-02-05 21:00
1310
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...
2024-02-05 08:00
1211
Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business
SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...
2024-02-03 08:00
2091
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
Most Read
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6416
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6349
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
2024-04-12 20:08
4533
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3807